David J Gordon

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8057441/publications.pdf

Version: 2024-02-01

32 papers	2,505 citations	430442 18 h-index	433756 31 g-index
32 all docs	32 docs citations	32 times ranked	3963 citing authors

#	Article	IF	Citations
1	Causes and consequences of aneuploidy in cancer. Nature Reviews Genetics, 2012, 13, 189-203.	7.7	700
2	Supramolecular Structure in Full-Length Alzheimer's Î²-Amyloid Fibrils: Evidence for a Parallel Î²-Sheet Organization from Solid-State Nuclear Magnetic Resonance. Biophysical Journal, 2002, 83, 1205-1216.	0.2	309
3	Inhibition of Î²-Amyloid(40) Fibrillogenesis and Disassembly of Î²-Amyloid(40) Fibrils by Short Î²-Amyloid Congeners ContainingN-Methyl Amino Acids at Alternate Residuesâ€. Biochemistry, 2001, 40, 8237-8245.	1.2	257
4	AÎ²40-Lactam(D23/K28) Models a Conformation Highly Favorable for Nucleation of Amyloid. Biochemistry, 2005, 44, 6003-6014.	1.2	241
5	Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nature Neuroscience, 1999, 2, 984-988.	7.1	146
6	Peptideâ€Based Inhibitors of Amyloid Assembly. Methods in Enzymology, 2006, 413, 273-312.	0.4	126
7	Increasing the Amphiphilicity of an Amyloidogenic Peptide Changes the Î²-Sheet Structure in the Fibrils from Antiparallel to Parallel. Biophysical Journal, 2004, 86, 428-434.	0.2	119
8	Probing the Role of Backbone Hydrogen Bonding in Î²-Amyloid Fibrils with Inhibitor Peptides Containing Ester Bonds at Alternate Positions. Biochemistry, 2003, 42, 475-485.	1.2	108
9	Gas-Phase Photochemistry of the Photoactive Yellow Protein Chromophoretrans-p-Coumaric Acid. Journal of the American Chemical Society, 2002, 124, 6194-6201.	6.6	71
10	pH dependent self assembly of Î²-amyloid(10-35) and Î²-amyloid(10-35)-PEG3000. Journal of Applied Crystallography, 2000, 33, 535-539.	1.9	43
11	Inhibition of the ATRâ€“CHK1 Pathway in Ewing Sarcoma Cells Causes DNA Damage and Apoptosis via the CDK2-Mediated Degradation of RRM2. Molecular Cancer Research, 2020, 18, 91-104.	1.5	43
12	Spatial Separation of Î²-Sheet Domains of Î²-Amyloid:Â Disruption of Each Î²-Sheet byN-Methyl Amino Acidsâ€. Biochemistry, 2006, 45, 9485-9495.	1.2	42
13	Gene expression signature based screening identifies ribonucleotide reductase as a candidate therapeutic target in Ewing sarcoma. Oncotarget, 2016, 7, 63003-63019.	0.8	31
14	CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. International Journal of Molecular Sciences, 2020, 21, 3018.	1.8	30
15	mTORC1/2 and Protein Translation Regulate Levels of CHK1 and the Sensitivity to CHK1 Inhibitors in Ewing Sarcoma Cells. Molecular Cancer Therapeutics, 2018, 17, 2676-2688.	1.9	27
16	A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin. American Journal of Hematology, 2009, 84, 771-772.	2.0	24
17	Inhibition of CHK1 sensitizes Ewing sarcoma cells to the ribonucleotide reductase inhibitor gemcitabine. Oncotarget, 2017, 8, 87016-87032.	0.8	23
18	Pharmacologic Ascorbate Primes Pancreatic Cancer Cells for Death by Rewiring Cellular Energetics and Inducing DNA Damage. Molecular Cancer Research, 2019, 17, 2102-2114.	1.5	21

#	Article	IF	Citations
19	Modeling the initiation of Ewing sarcoma tumorigenesis in differentiating human embryonic stem cells. Oncogene, 2016, 35, 3092-3102.	2.6	20
20	Aurea Mediocritas: The Importance of a Balanced Genome. Cold Spring Harbor Perspectives in Biology, 2014, 6, a015842-a015842.	2.3	19
21	Familial British Dementia: Expression and Metabolism of BRI. Annals of the New York Academy of Sciences, 2000, 920, 93-99.	1.8	18
22	Drug conjugated nanoparticles activated by cancer cell specific mRNA. Oncotarget, 2016, 7, 38243-38256.	0.8	17
23	SN-38 Conjugated Gold Nanoparticles Activated by Ewing Sarcoma Specific mRNAs Exhibit In Vitro and In Vivo Efficacy. Bioconjugate Chemistry, 2018, 29, 1111-1118.	1.8	16
24	The translational repressor 4E-BP1 regulates RRM2 levels and functions as a tumor suppressor in Ewing sarcoma tumors. Oncogene, 2021, 40, 564-577.	2.6	13
25	Disruption of dNTP homeostasis by ribonucleotide reductase hyperactivation overcomes AML differentiation blockade. Blood, 2022, 139, 3752-3770.	0.6	12
26	Structure of Spin-Labeled Methylmethanethiolsulfonate in Solution and Bound to TEM-1 Î²-Lactamase Determined by Electron Nuclear Double Resonance Spectroscopyâ€. Biochemistry, 2002, 41, 797-808.	1.2	7
27	Eltrombopag inhibits the proliferation of Ewing sarcoma cells via iron chelation and impaired DNA replication. BMC Cancer, 2020, 20, 1171.	1.1	7
28	Combination therapies for MPNSTs targeting RABL6A-RB1 signaling. Oncotarget, 2021, 12, 10-14.	0.8	5
29	Development of Secondary Acute Myeloid Leukemia in a Pediatric Patient Concurrently Receiving Primary Therapy for Ewing Sarcoma. Journal of Pediatric Hematology/Oncology, 2017, 39, e370-e372.	0.3	4
30	Oncogenic RABL6A promotes NF1-associated MPNST progression in vivo. Neuro-Oncology Advances, 2022, 4, vdac047.	0.4	3
31	Inhibitor of DNA binding 2 (ID2) regulates the expression of developmental genes and tumorigenesis in ewing sarcoma. Oncogene, 2022, 41, 2873-2884.	2.6	2
32	Preclinical efficacy of prexasertib in acute lymphoblastic leukemia. British Journal of Haematology, 2021, 194, 1094-1098.	1.2	1